Phase III, open-label, multi-center study to assess the pharmacodynamic (PD), pharmacokinetic (PK) and safety of Zoreline 10.8 mg goserelin subcutaneous implant (Novalon) in male subjects with prostate cancer.
Latest Information Update: 11 Apr 2022
At a glance
- Drugs Goserelin (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Pharmacodynamics; Registrational
- Sponsors Novalon
Most Recent Events
- 11 Apr 2022 This trial has been completed in Belgium, according to European Clinical Trials Database record. (06-04-2020)
- 11 Apr 2022 New trial record